Journal Article

<i>In vitro</i> and <i>in vivo</i> release of ciprofloxacin from osteoconductive bone defect filler

Tatu J. Mäkinen, Minna Veiranto, Petteri Lankinen, Niko Moritz, Jari Jalava, Pertti Törmälä and Hannu T. Aro

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 6, pages 1063-1068
Published in print December 2005 | ISSN: 0305-7453
Published online October 2005 | e-ISSN: 1460-2091 | DOI: https://dx.doi.org/10.1093/jac/dki366
In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler

Show Summary Details

Preview

Objectives: Impregnation of antimicrobial agents within biodegradable carriers with osteoconductive properties could provide the means for one-stage surgical treatment of osteomyelitis. In this study, the in vitro and in vivo antibiotic release from this type of bone defect filler was characterized.

Methods: Cylindrical pellets (2.5 × 1.5 mm) were manufactured from bioabsorbable poly(l-lactide-co-glycolide) (PLGA) matrix, ciprofloxacin [8.3 ± 0.1% (w/w)] and osteoconductive bioactive glass microspheres (90–125 μm) [27 ± 2% (w/w)]. In vitro studies were carried out to delineate the release profile of the antibiotic. The antimicrobial activity of the release antibiotic was verified with MIC testing. In a time-sequence study in the rabbit, pellets were surgically implanted in the proximal tibia and the antibiotic concentrations achieved in bone were measured at 1, 2, 3, 4, 5 and 6 months.

Results: In vitro elution studies showed sustained release of ciprofloxacin at a therapeutic level (>2 μg/mL) over a time period of 4 months. The released ciprofloxacin had maintained its antimicrobial capacity against five standard ATCC strains. In vivo, the delivery system produced high local bone concentrations (247.9 ± 91.0 μg/g of bone) for a time period of 3 months with no significant systemic exposure. Histomorphometry and micro-CT imaging confirmed new bone formation around the pellets within 3 months as a sign of an independent osteoconductive property of the composite.

Conclusions: The tested composite seems to be a promising option for local therapy of surgically treated bone infections. The main advantages are the antibiotic release for a definite time period with therapeutic concentrations, which may minimize slow residual release at suboptimal concentrations.

Keywords: antimicrobial delivery; bioactive glass; osteomyelitis

Journal Article.  4785 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.